<table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="tbl22" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>F Test statistic</th><th>Partial &#951;<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A Priori power</th><th>Total sample size</th></tr></thead><tbody><tr><td>pAKT</td><td>F(1,12) = 15.9141 (main effect: growth factor)</td><td>0.5701</td><td>1.151574</td><td>85.9%<xref ref-type="table-fn" rid="tblfn16"><sup>a</sup></xref></td><td>11<xref ref-type="table-fn" rid="tblfn16"><sup>a</sup></xref> (6 groups)</td></tr><tr><td>pERK</td><td>F(1,12) = 13.0042 (main effect: growth factor)</td><td>0.5201</td><td>1.041042</td><td>85.0%<xref ref-type="table-fn" rid="tblfn17"><sup>b</sup></xref></td><td>12<xref ref-type="table-fn" rid="tblfn17"><sup>b</sup></xref> (6 groups)</td></tr><tr><td>pERK</td><td>F(2,12) = 7.5790 (main effect: BRAF/MEK inhibitor)</td><td>0.5581</td><td>1.123813</td><td>82.9%<xref ref-type="table-fn" rid="tblfn18"><sup>c</sup></xref></td><td>13<xref ref-type="table-fn" rid="tblfn18"><sup>c</sup></xref> (6 groups)</td></tr><tr><td>pMET (Tyr1349)</td><td>F(1,12) = 9.4520 (main effect: growth factor)</td><td>0.4406</td><td>0.887485</td><td>82.8%<xref ref-type="table-fn" rid="tblfn19"><sup>d</sup></xref></td><td>14<xref ref-type="table-fn" rid="tblfn19"><sup>d</sup></xref> (6 groups)</td></tr></tbody></table><table-wrap-foot><fn id="tblfn16"><label>a</label><p>36 total will be used based on the planned comparison calculations making the power 99.9%.</p></fn><fn id="tblfn17"><label>b</label><p>36 total will be used based on the planned comparison calculations making the power 99.9%.</p></fn><fn id="tblfn18"><label>c</label><p>36 total will be used based on the planned comparison calculations making the power 99.9%.</p></fn><fn id="tblfn19"><label>d</label><p>36 total will be used based on the planned comparison calculations making the power 99.9%.</p></fn></table-wrap-foot></table-wrap>